SAN DIEGO, June 6 /PRNewswire-FirstCall/ -- Sequenom, Inc. (Nasdaq: SQNM - News), the developer of advanced, proprietary genetic analysis systems and methodologies that translate genomic science into superior solutions for non-invasive prenatal testing, biomedical research, molecular medicine, and agricultural applications, today announced the closing of its $33 million private placement financing with four institutional investors. Oppenheimer & Co., Inc. was the placement agent. The investment in Sequenom included the sale and issuance of 19,999,998 shares of common stock and warrants to purchase an additional 11,999,999 shares of common stock. The investors were Pequot Private Equity Fund IV, L.P., ComVest Investment Partners II LLC, LB I Group, Inc. (an affiliate of Lehman Brothers), and Siemens Venture Capital GmbH.
